$1.04 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
-Total revenue in the last quarter.
$-77.5 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-5.01Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-2.8xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-78 MillionEarnings before interest expenses and taxes in the last quarter.
393The number of full time employees.
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Brokerages expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings per share (EPS) of ($1.10) for the current quarter, according to Zacks Investment Research. Zero analysts have provided ...The Olympia Report, 3 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform...Business Wire, about 1 month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments...Business Wire, about 1 month ago